Marine Sulfated Polysaccharides: Preventive and Therapeutic Effects on Metabolic Syndrome: A Review.

Abstract

Metabolic syndrome is the pathological basis of cardiovascular and cerebrovascular diseases and type 2 diabetes. With the prevalence of modern lifestyles, the incidence of metabolic syndrome has risen rapidly. In recent years, marine sulfate polysaccharides (MSPs) have shown positive effects in the prevention and treatment of metabolic syndrome, and they mainly come from seaweeds and marine animals. MSPs are rich in sulfate and have stronger biological activity compared with terrestrial polysaccharides. MSPs can alleviate metabolic syndrome by regulating glucose metabolism and lipid metabolism. In addition, MSPs prevent and treat metabolic syndrome by interacting with gut microbiota. MSPs can be degraded by gut microbes to produce metabolites such as short chain fatty acids (SCFAs) and free sulfate and affect the composition of gut microbiota. The difference between MSPs and other polysaccharides lies in the sulfation pattern and sulfate content, therefore, which is very important for anti-metabolic syndrome activity of MSPs. This review summarizes the latest findings on effects of MSPs on metabolic syndrome, mechanisms of MSPs in treatment/prevention of metabolic syndrome, interactions between MSPs and gut microbiota, and the role of sulfate group and sulfation pattern in MSPs activity. However, more clinical trials are needed to confirm the potential preventive and therapeutic effects on human body. It may be a better choice to develop new functional foods containing MSPs for dietary intervention in metabolic syndrome.

• Authors: Ying Li, Juan Qin, Yinghui Cheng, Dong Lv, Meng Li, Yanxia Qi, Jing Lan, Qiancheng Zhao, Zhibo Li
• Journal: Marine drugs (Mar Drugs) Vol. 19 Issue 11 (Oct 27 2021) ISSN: 1660-3397 [Electronic] Switzerland
• PMID: 34822479 (Publication Type: Journal Article, Review)

Chemical References

• Polysaccharides

Topics

• Animals
• Aquatic Organisms
• Diabetes Mellitus, Type 2 (drug therapy)
• Gastrointestinal Microbiome (drug effects)
• Metabolic Syndrome (drug therapy)
• Polysaccharides (chemistry, pharmacology, therapeutic use)